Cargando…
Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
Chromium has long been known as an enhancer of insulin action. However, the role of chromium in the development of type 2 diabetes mellitus (T2DM) in humans remains controversial. The current study aimed to examine the associations of plasma chromium levels with T2DM and pre-diabetes mellitus (pre-D...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372957/ https://www.ncbi.nlm.nih.gov/pubmed/28304331 http://dx.doi.org/10.3390/nu9030294 |
_version_ | 1782518726676971520 |
---|---|
author | Chen, Sijing Jin, Xiaoling Shan, Zhilei Li, Shuzhen Yin, Jiawei Sun, Taoping Luo, Cheng Yang, Wei Yao, Ping Yu, Kaifeng Zhang, Yan Cheng, Qian Cheng, Jinquan Bao, Wei Liu, Liegang |
author_facet | Chen, Sijing Jin, Xiaoling Shan, Zhilei Li, Shuzhen Yin, Jiawei Sun, Taoping Luo, Cheng Yang, Wei Yao, Ping Yu, Kaifeng Zhang, Yan Cheng, Qian Cheng, Jinquan Bao, Wei Liu, Liegang |
author_sort | Chen, Sijing |
collection | PubMed |
description | Chromium has long been known as an enhancer of insulin action. However, the role of chromium in the development of type 2 diabetes mellitus (T2DM) in humans remains controversial. The current study aimed to examine the associations of plasma chromium levels with T2DM and pre-diabetes mellitus (pre-DM). We conducted a case-control study involving 1471 patients with newly diagnosed T2DM, 682 individuals with newly diagnosed pre-DM, and 2290 individuals with normal glucose tolerance in a Chinese population from 2009 to 2014. Plasma chromium was measured by inductively coupled plasma mass spectrometry. Plasma chromium levels were lower in the T2DM and pre-DM groups than in the control group (median: 3.68 μg/L, 3.61 μg/L, 3.97 μg/L, respectively, p < 0.001). After adjustment for potential confounding factors, the odds ratios (95% confidence interval) for T2DM across increasing quartiles of plasma chromium levels were 1 (referent), 0.67 (0.55–0.83), 0.64 (0.51–0.79), and 0.58 (0.46–0.73), respectively (p for trend <0.001). The corresponding odds ratios (95% confidence interval) for pre-DM were 1 (referent), 0.70 (0.54–0.91), 0.67 (0.52–0.88), and 0.58 (0.43–0.78), respectively (p for trend < 0.001). Our results indicated that plasma chromium concentrations were inversely associated with T2DM and pre-DM in Chinese adults. |
format | Online Article Text |
id | pubmed-5372957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53729572017-04-05 Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study Chen, Sijing Jin, Xiaoling Shan, Zhilei Li, Shuzhen Yin, Jiawei Sun, Taoping Luo, Cheng Yang, Wei Yao, Ping Yu, Kaifeng Zhang, Yan Cheng, Qian Cheng, Jinquan Bao, Wei Liu, Liegang Nutrients Article Chromium has long been known as an enhancer of insulin action. However, the role of chromium in the development of type 2 diabetes mellitus (T2DM) in humans remains controversial. The current study aimed to examine the associations of plasma chromium levels with T2DM and pre-diabetes mellitus (pre-DM). We conducted a case-control study involving 1471 patients with newly diagnosed T2DM, 682 individuals with newly diagnosed pre-DM, and 2290 individuals with normal glucose tolerance in a Chinese population from 2009 to 2014. Plasma chromium was measured by inductively coupled plasma mass spectrometry. Plasma chromium levels were lower in the T2DM and pre-DM groups than in the control group (median: 3.68 μg/L, 3.61 μg/L, 3.97 μg/L, respectively, p < 0.001). After adjustment for potential confounding factors, the odds ratios (95% confidence interval) for T2DM across increasing quartiles of plasma chromium levels were 1 (referent), 0.67 (0.55–0.83), 0.64 (0.51–0.79), and 0.58 (0.46–0.73), respectively (p for trend <0.001). The corresponding odds ratios (95% confidence interval) for pre-DM were 1 (referent), 0.70 (0.54–0.91), 0.67 (0.52–0.88), and 0.58 (0.43–0.78), respectively (p for trend < 0.001). Our results indicated that plasma chromium concentrations were inversely associated with T2DM and pre-DM in Chinese adults. MDPI 2017-03-17 /pmc/articles/PMC5372957/ /pubmed/28304331 http://dx.doi.org/10.3390/nu9030294 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Sijing Jin, Xiaoling Shan, Zhilei Li, Shuzhen Yin, Jiawei Sun, Taoping Luo, Cheng Yang, Wei Yao, Ping Yu, Kaifeng Zhang, Yan Cheng, Qian Cheng, Jinquan Bao, Wei Liu, Liegang Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study |
title | Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study |
title_full | Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study |
title_fullStr | Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study |
title_full_unstemmed | Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study |
title_short | Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study |
title_sort | inverse association of plasma chromium levels with newly diagnosed type 2 diabetes: a case-control study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372957/ https://www.ncbi.nlm.nih.gov/pubmed/28304331 http://dx.doi.org/10.3390/nu9030294 |
work_keys_str_mv | AT chensijing inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT jinxiaoling inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT shanzhilei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT lishuzhen inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT yinjiawei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT suntaoping inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT luocheng inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT yangwei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT yaoping inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT yukaifeng inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT zhangyan inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT chengqian inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT chengjinquan inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT baowei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy AT liuliegang inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy |